Published: August 05, 2011
CytoDyn Announces Provisional FIV Patent Filing
LUTZ, Fla. - (BUSINESS WIRE) - CytoDyn Inc. (the "Company" ) (OTC:CYDY) announced today that on June 17,
2011 it filed for a provisional patent in the United States for the
treatment of FIV, a retroviral infection in cats. The Company intends to
develop this product as part of its wholly owned subsidiary CytoDyn
Veterinary Medicine, LLC which the Company hopes will allow it to expand
its science into a different market segment. The Company's primary
target will be a monoclonal antibody for the treatment of FIV infection
in cats. According to Kenneth J. Van Ness, the Company's President and
Chief Executive Officer, "We believe our technology may allow us to
target cell derived molecules that the Company thinks may be essential
for retroviral infections."
Forward Looking Statements
The Press Release includes forward-looking statements and includes
forward-looking information within the meaning of United States
securities laws. These statements and this information represent the
Company's intentions, plans, expectations and beliefs, and are subject
to risks, uncertainties and other factors, of which many are beyond the
Company's control. These factors could cause actual results to differ
materially from such forward-looking statements or forward-looking
information. The words "believe," "estimate," "expect," "intend,"
"anticipate," "foresee," "plan," and similar expressions and variations
thereof, identify certain of such forward-looking statements or
forward-looking information, which speak only as of the date on which
they are made. The Company disclaims any intention or obligation to
publicly update or revise any forward-looking statements or
forward-looking information, whether as a result of new information,
future events or otherwise, except as required by applicable law.
Readers are cautioned not to place undue reliance on these
forward-looking statements or on this forward-looking information.
CytoDyn Inc.
Douglas E. Jacobson
Controller
(813) 527-6969
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
